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Abstract 
∆9-Tetrahydrocannabinol (THC) and cannabidiol (CBD) are phytocannabinoids that have a 
potential impact in cancer treatments. Studies have shown that certain cannabinoids cause cancer 
cells to die, but only with selective concentrations, which have not been well documented. The 
first study of this thesis was to determine the exact concentration of CBD and THC needed to kill 
human MCF-7 breast cancer cells, rather than creating mass multiplication leading to more 
growth of the cancer. To conduct this experiment, cell culture was performed with a MCF-7 
breast cancer cell line. The treatment groups were treated with CBD or THC at varying 
concentrations including 0.1, 1, 10 and 100 µM. Observations were made by using tetrazolium 
dye (MTT assay), which is a colorimetric assay for measuring cell proliferation. Additionally, as 
an alternative approach to assess cell death, Western blot was performed. MCF-7 cells were 
analyzed for apoptosis through Western blotting by detecting poly ADP ribose polymerase 
(PARP) cleavage. CBD inhibited MCF-7 breast cancer growth, whereas THC stimulated MCF-7 
breast cancer cell proliferation. MTT assay and Western blot displayed the same pattern with 
CBD being the most effective treatment, but with different effective concentrations. The MTT 
assay method suggested that 1 µM cannabidiol was the most effective, whereas the Western blot 
indicated that 10 µM cannabidiol was the most effective. These results are inconstant and they 
have not been replicated. This research is a continuation in which experiments will narrow the 
effective concentration needed to cause cancer cells apoptosis. Favorable findings may provide 
an accessible and affordable cannabinoid-based treatment for patients.  
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The Effects of Cannabidiol and Tetrahydrocannabinol Concentration on Breast Cancer 
Cells 
 
 One in eight women (about 12.5%) will develop invasive breast cancer over the course of 
her lifetime (U.S Breast Cancer Statistics, 2018) in the United States. Not only is breast cancer 
deadly, but breast cancer can spread to other parts of the body such as lymph nodes, lungs, and 
other organs. Breast cancer cells in the lymph nodes suggest an increased risk of cancer 
metastasis and decreased rate of survival. Breast cancer is treated in various ways such as 
radiation and surgical removal of the breast, which leaves the survivors with physical and 
emotional trauma. Chemotherapy is another common treatment but has side effects such as hair 
lost, easy bruising, bleeding, and cognitive disorders which can affect concentration and focus 
(American Cancer Society, 2016). Due to these negative side effects, researchers have been 
looking for supportive alternate treatments that are equally effective but without the side effects. 
One possibility: Cannabis-derived cannabinoid drugs. Cannabinoids are being investigated 
(Qamri et al., 2009) as anticancer treatments with fewer side effects than conventional 
chemotherapy.  
Purpose and Significance  
Studies suggest that cannabinoids can kill cancer cells, and researchers have proposed 
that the concentration of cannabinoids makes a difference in determining cancer cell apoptosis 
(cell death), however optimization of the cannabinoids concentration is necessary (Sarfaraz, 
Adhami, Syned, Afaq, & Murkhtar, 2008). Sarfaraz et al. (2008) proposed that the 
overexpression of cannabinoid receptors (CB1 and CB2: G-protein couple receptors located 
throughout the body) may lead to cancer cell death, but little or no expression of these receptors 
could lead to cell proliferation and metastasis due to the suppression of the antitumor immune 
response. It is unknown how the concentrations of two common cannabinoids--cannabidiol 
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(CBD) and ∆9-tetrahydrocannabinol (THC) affect cancer cells. Therefore, studying the effect of 
varying concentrations of CBD and THC on breast cancer cells could offer a potential avenue for 
new treatments of this disease.  
 Because Cannabis is easily grown, the cost of cannabinoid-based cancer treatment could 
potentially be much lower than other forms of chemotherapy (Gringsppoon, 1999). Furthermore, 
cannabinoid drugs are known to reduce many side effects associated with other treatments, such 
as pain, loss of appetite, nausea, and vomiting (Rocha, Stefano, Haiek, Oliveira & Da Silveria, 
2008; Tramèr et al., 2001; Ware et al., 2010), which will benefit cancer patients by preventing 
them from taking additional medications for side effects. The use of cannabinoid drugs can also 
potentially void the need of traumatic surgeries. Lastly, when an effective concentration is 
known for treatment, cannabinoids should work more efficiently than most other cancer 
treatments because they inhibit the cancer growth without interfering with normal cells (Kogan, 
2005). Not only are cannabinoid drugs affordable and have anti-proliferative properties, they can 
reduce side effects associated with other treatments making cannabinoid drugs a potential 
treatment to research and develop.  
Review of Literature 
Cancer Pathogenesis 
During the cell cycle, there are checkpoints which are responsible for making sure the 
cell is capable to function and regulate when necessary. At the checkpoint, if a cell has any 
damage or cannot serve its purpose, the cell is marked for apoptosis. Apoptosis is a normal 
physiological process which removes unwanted cells by programming the cell’s death. Some 
damaged cells escape the checkpoint without being marked for apoptosis. These abnormal cells 
can grow out of proportion and can become cancer cells (Visconti et al., 2016).  
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 Cancer cells are cells that have lost the ability to function normally or die but can still 
divide. Uncontrollable growth forms a mass of tissue called a tumor. Because cancer cells are 
similar to normal cells, it is difficult to selectively kill them without affecting normal cells 
(Yasukawa, 2014). When the cancer cells spread to different regions of the body, it is called 
metastasis.  Cyclin E is a regulator of cell cycle and, with cyclin-dependent kinase (cdk) 2, is 
important for the G1/S transition during the cell cycle. In tumors, there is normally an 
overexpression of the cyclin E protein causing cell proliferation and bypassing the checkpoint 
leading to cancer.  
There are five types of cancer classified by their tissue/cell types of origin, which are 
sarcomas, leukemia, lymphomas, melanoma, and carcinomas (Movva, 2015). Carcinomas, which 
was the focus of this study, develop in the epithelial cells, which start from the skin or epithelial 
tissue and spread to the internal organs and are caused by the damage of DNA resulting in a 
mutation (Rosenbreg, 1987). MCF-7, which is a human breast adenocarcinoma cell line, was the 
selected cell type utilized. Breast cancer is the most common cancer and the leading cause of 
cancer death in American women. American Cancer Society estimated 41,400 deaths occurred in 
2018 among males and females due to breast cancer.  
  The method of cancer treatment is determined based on the cancer type, stage of cancer 
development, and the person’s health. The three common cancer treatments are radiation, 
surgery, and chemotherapy. Radiation therapy uses high energy waves to makes small breaks in 
the DNA inside cancer cells. During this process, abnormal cells are destroyed and new, normal 
cells replace the dead ones (Lawrence, Ten Haken & Giaccia, 2008). Surgery is used to remove a 
tumor prior to metastasis, whereas chemotherapy uses drugs to inhibit cancer cell function (Ho 
Im et al., 2016). 
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Cannabinoids 
 Cannabinoids are compounds originally discovered in the plant Cannabis sativa. They 
are potential chemotherapeutic agents being investigated to treat cancer. The discovery of 
cannabinoids occurred in the 1940s, and the receptors for these molecules were discovered in the 
mid-1980 (Pertwee, 2006). To date, approximately 113 cannabinoids have been isolated from 
Cannabis (Namdar et al., 2018). 
There are three primary types of cannabinoids: endocannabinoids, synthetic cannabinoids, 
and phytocannabinoids (Qamri et al., 2009). Endocannabinoids are endogenous cannabinoids 
that the human body synthesizes and releases, which also interact with the CB1 and CB2 
receptors. Anandamide is a type of endocannabinoid that binds to CB1 and activates the receptor 
(Pertwee, 2008). Synthetic cannabinoids are designed for research purposes, and they also 
interact with the CB1 and CB2 receptors (Seely, Lapoint, Moran, & Fattore, 2012). Synthetic 
cannabinoids are mildly psychoactive because of their cannabimimetic properties (Grigoryev et 
al., 2011).  
Phytocannbiniods are cannabinoids that occur naturally in the Cannabis plant; the most 
thoroughly investigated phytocannabinoids are THC and CBD (Figure 1) (Borgelt et al., 2013). 
CBD has a significantly different action than THC (Gertsch, Pertwee & Di Marzo, 2010). THC 
directly activates the CB1 receptor, which causes a change in brain function due to its 
psychoactive properties. Unlike THC, CBD has a low affinity for the CB1/CB2 receptors. 
However, it causes cellular modulation that leads to an indirect interaction with the CB1 receptor 
(Pacher, Batkai, & Kunos, 2006). CBD induces endogenous neurotransmitter uptake, which is 
responsible for signal transmission in the brain (Moreira et al., 2011).
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Figure 1. THC and CBD chemical structures.         
                                                                                     
 Cannabinoids serve a purpose in pharmaceutical science, even though Cannabis is just 
becoming accepted by society (Gupta, 2014). Due to powerful therapeutic properties used to 
treat several medical conditions, cannabinoids have been contributing to pharmaceutical benefits 
since 1850. Research has shown that cannabinoids can contribute to factors that help the body 
respond to injury, defend against viruses and bacteria, and repair damaged tissues in the body 
(Nagarkatti, Pandey, Rieder, Hegde, & Nagarkatti, 2009). Cannabinoids can also regulate energy 
in the body by activating the 5-hydroxytryptamine (serotonin) receptor, which contributes to the 
reduction of addiction, anxiety, depression, nausea, pain, and vomiting as well as improves 
appetite and sleep (Crippa et al., 2010).  
CBD and THC inhibit cancer metastasis by activating the CB1 and CB2 receptors (Patsos, 
Hicks, Greenhough, Williams, & Paraskeva, 2005). CB1 receptors are in the basal ganglia, brain, 
cerebellum, limbic system, and reproductive system. CB2 receptors are correlated with anti-
inflammatory processes and are, in addition to the locations mentioned, found in the spleen. CB2 
is expressed “on demand”, the modulation of CB2 levels is a common feature to cells of 
macrophage lineage as they participate in the inflammatory response and undergo differential 
gene expression and acquisition of distinctive functional properties (Cabral, 2009). 
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Cannabinoids and Cancer 
The mechanism by which cannabinoids directly kill breast cancer cells is currently 
unknown, but researchers have postulated a potential mechanism. Velasco et al. (2016) 
suggested a pathway in which cannabinoids might cause cancer cell apoptosis (Figure 2). THC 
stimulates the stress-regulated protein pathway, which enhances the inhibitory interaction of the 
pseudokinase homologue 3 with pro-survival kinases, Akt. This leads to inhibition of the 
mammalian target of rapamycin complex 1 and the subsequent stimulation of autophagy-
mediated cell death (Velasco et al., 2016).  
 Velasco et al. ( 2016) proposed the mechanism for glioma cancer cells. Even though the 
mechanism of how apoptosis occurs in breast cancer cells is not known, most cancer apoptosis 
probably follow a similar mechanism. Researchers have frequently determined that THC and 
CBD can kill cancer cells. However, the specific concentration of CBD and THC is rarely 
addressed. Sarfaraz et al. (2008) speculated that the concentration makes a difference in whether 
there will be apoptosis or proliferation in cancer cells.  
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Figure 2. The proposed mechanism of apoptosis caused by cannabinoids on glioma cells 
(Velasco et al., 2016). 
 
 
Sarfaraz et al. (2008) proposed that overexpressed CB1and CB2 receptors may lead to 
tumor destruction, but low or no expression of these receptors could lead to cell proliferation and 
metastasis because of the suppression of the antitumor immune response. This suggests that 
cannabinoids as an anticancer treatment will not exhibit the side effects associated with current 
cancer treatments, making cannabinoids a promising contribution to current cancer therapies. 
Because the concentration of cannabinoids affects cancer cells, the precise concentration of THC 
and CBD needed to cause apoptosis of the breast cancer cells must be examined.  
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Methods 
This study was conducted at the University of Northern Colorado in the Department of 
Chemistry and Biochemistry and the School of Biological Sciences. Cell culture was performed 
with a MCF-7 human breast cancer cell line obtained from Bio-Rad (Bio Rad Laboratories, 
Hercules, CA, USA). Cultures were kept in an incubator at 37 ºC with 95% humidified air and 
5% CO2. Two controls for this experiment were used: cells in Roswell Park Memorial Institute 
(RPMI) culture medium without cannabinoids and cells in the same medium with ethanol. The 
ethanol was added to determine the effect ethanol had on cancer cells, due to the fact the drugs 
were dissolved in ethanol. Two treatment groups were also used to compare CBD and THC. 
These treatment groups were treated with CBD or THC at varying concentrations including 0.1, 
1, 10 and 100 micromolar. These concentrations are arbitrarily chosen because there is not an 
established baseline of concentrations that might affect the cancer cells. To study whether CBD 
and THC cause apoptosis or proliferation in MCF-7 cells, an MTT assay was performed to 
determine cell proliferation through a colorimetric measurement of metabolic mitochondrial 
activity.  
 Media 
 Fresh media was made by adding either a mixture of fetal bovine and horse sera (FBE, 
cat. No. VWR) or to a RPMI base. Additionally, penicillin 100 unit/L/streptomycin (100 ug/L 
(ThermoFisher, 10378016), sodium pyruvate 1 mM (ThermoFisher, 11360070), bovine insulin 
10 mg/mL (ThermoFisher, 12585014), L-glutamine 2 mM (ThermoFisher, 25030081), Hepes 
(buffer agent) 10 mM (ThermoFisher, 15630080) and 2-mercaptoethanol 0.142 M 
(ThermoFisher, 35602BID) were added to the RMPI to provide a complete media (cRPMI) with 
everything the MCF-7 cancer cells need to grow. 
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Cell Growth and Passing 
After incubation for 24 hours (37 ℃, 95% humidified air, 5% CO2), old medium was 
discarded and cells were trypsinized by adding 3 mL of trypsin (1x) concentration 
(ThermoFisher, 25200-056) to the flask and incubating the flasks at 37 ºC and 5% CO2 for 1-2 
min, until cells lifted from the culture flask surface. Six mL of fresh media were added to each 
flask to neutralize the trypsin reaction. The cells, now in fresh media, were centrifuged at 1200 
rpm in conical tubes for 5 min. Supernatant was discarded, and the cell pellets were re-suspended 
in 1 mL of fresh media each. A 10 µL sample of MCF-7 cells was stained with trypan blue (1:1) 
and counted using a Countess II Automated Cell Counter. These results were used to determine 
the cell density to determine the volume containing the proper number of cells needed to be 
grown in each well. The calculated number of the cells were then re-suspended in fresh media 
(12 mL in the T-75 flask), then transferred constantly to 96 wells plates and incubated until they 
are 80% confluent (roughly 48-64 hr.). 
Adding Cannabinoids to the Cancer Cell Cultures 
The first control group was suspended in media without any cannabinoids or ethanol (the 
vehicle control); the second control group were suspended in media with ethanol equal to the 
amount of ethanol in which the cannabinoids were delivered. Each concentration treatment had 
three replicates. For the first treatment of breast cancer cells, 0.1 µM CBD was added to each of 
the three wells in the first column. The second column had 1 µM of CBD, while the third column 
had 10 µM CBD, and lastly the fourth column had 100 µM of CBD. A second set of breast 
cancer cells followed the same protocol with the concentrations of THC using a different plate.   
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MTT Assay 
The plates were incubated (37 ºC, 95% humidified air, 5% CO2) for 24 hours. 
Tetrazolium dye- MTT assay (ThermoFisher, V13154) was added to the MCF-7 cancer cells 
which measures cell metabolic activity to determine the actual percent of the MCF-7 cancer cell 
apoptosis (Kowalczewska et al., 2016).  
Western Blot 
 The protocol by Pullen et al.  (2012) was used in determining cell viability through 
Western blot. MCF-7 cells were analyzed for apoptosis though Western blotting by detecting 
PARP cleavage. This allowed comparison of control group apoptosis (baseline) to cells treated 
with cannabinoids and served as a preliminary measure of induction of apoptosis, which could be 
the basis for later studies examining the timing of apoptosis. MCF-7 cells were treated with lysis 
buffer (from Cell Signaling Technology, a detergent containing phosphatase and protease 
inhibitors to preserve protein structure) (ThermoFisher, 89900) to obtain intracellular proteins; 
immediately after lysis, samples were microcentrifuged for 5 min at 13,000xg. Proteins were 
denatured, and chemically reduced at 95-100 ºC in 1X Laemmli buffer containing β-
mercaptoethanol for 10 min then cooled on ice. The supernatant was subjected to SDS-PAGE 
with 4%-20% Tris-glycine polyacrylamide gels for resolution based on size (kDa), and then 
electro-transferred to a nitrocellulose membrane. Twenty-five milliliters of 1X Tris-buffered 
saline (TBS) were used to wash the nitrocellulose membrane for 5 min at room temperature. 
Then, to block unspecific binding, the membrane was incubated at room temperature for 1 h in a 
mixture of TBS with 5% (v/v) milk and 0.05% (v/v), (TBST). The membrane was then rinsed 
with TBST and incubated with a primary antibody specific for detecting human poly (ADP-
robosyl) polymerase 1 at 1:1000) diluted in 1X TBST containing 5% bovine serum albumin 
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(BSA), with gentle agitation overnight at 4 °C. The membrane was washed three times for 5 min 
each with TBST. The membrane was then incubated for 45 min with anti-rabbit IgG conjugated 
to horse radish peroxidase (HRP). TBST was used to wash the membrane and detection was 
made by using enhanced chemiluminescence substrate activated by HRP (PerkinElmer, Rodgau, 
Germany). Densitometric analysis was performed using ImageJ software (National Institutes of 
Health, Bethesda, MD, USA).  
Statistical Analysis 
An ANOVA was performed to compared cannabinoid concentrations among each other 
and with control to determine if there is a significant difference in percent of the breast cancer 
cell death in both MTT assay and Western blot. Poc-host test was performed to determine which 
effects due to concentrations differ from one another. The treatment groups were compared with 
the control, since the control was set as the standard.   
 
Results 
 The first study (Agyemang, D., & Hyslop, R., in press) determined the exact 
concentration of CBD and THC needed to kill MCF-7 breast cancer cells. CBD was more 
effective at stimulating apoptosis compared to THC. However, the most effective concentration 
of CBD varied between the MTT assay and the Western blot assay. Since the THC was not as 
effective as we predicted, we could test the THC in higher concentrations in the future to gauge 
effectiveness. Because these are preliminary results, the assays will need to be replicated. This 
study will be replicating to determine if the basic findings of the original work are accurate. Due 
to the therapeutic potential of CBD and THC, the findings of this study could contribute to the 
ever-growing body of knowledge regarding cancer treatments. 
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MTT Assay 
 The MTT assay detects the proliferation of MCF-7 breast cancer cells. As the 
proliferation increases, it indicates that the concentration causes stimulation of proliferation in 
the MCF-7 breast cancer cells. The lower proliferation indicated that the MCF-7 breast cancer 
cells were inhibited by the concentration of the CBD or THC. The media was the control, which 
showed typical/expected proliferation of breast cancer cells. As illustrated in Figure 3, CBD is 
the more effective inducer of apoptosis of the MCF-7 breast cancer cells compared to the THC 
and control. The CBD and THC concentrations at 100 µM were the most effective among the 
concentrations. 
        However, THC concentrations had mixed effects on the MCF-7 breast cancer cells. At 10 
µM, THC stimulated the cancer cell growth compared to media alone and that is the opposite 
effect hypothesized.  Nevertheless, the rest of the THC concentrations had no effect on the 
proliferation of the MCF-7 breast cancer cell. 
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Figure 3. MCF-7 proliferation as a function of CBD and THC. The first bar of each 
concentration is CBD (orange), whereas THC (blue) is the next bar of each concentration.      
    
Western Blot 
The Western blot assessment illustrates the ratio between cleaved and uncleaved parp 
protein. The ratio is directly proportional to the apoptosis of the MCF-7 breast cancer cells. The 
higher ratio of the cleaved to uncleaved PARP protein indicates the apoptosis of the breast 
cancer cells with the influence by CBD or THC.  
 As illustrated in Figure 4, THC concentration caused more apoptosis in MCF-7 breast 
cancer cells compared to CBD. However, CBD and THC concentrations at 0.1 µM showed an 
increase in the ratio of the cleaved to uncleaved PARP protein indicating that there is an 
apoptosis of breast cancer. A decrease in ratio shows no changes in MCF-7 breast cancer cells or 
perhaps stimulation occurs, leading to proliferation of the MCF-7 breast cancer cells. As 
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illustrated in Figure 4, CBD concentrations of 1 µM and 100 µM showed a decrease in the ratio 
which indicates that no apoptosis occurred or perhaps a proliferation of the MCF-7 breast cancer 
cells.  
 
Figure 4. Detection of Parp-protein cleavage. An increase in the bar graph, higher than the 
media, indicates MCF-7 breast cancer cell apoptosis. CBD (orange), THC (blue), and the 
Controls (green). 
 
Statistical Analysis 
ANOVA - MTT Assay  
 A t-test of CBD or THC to media show no significant different, however comparison of 
each concentration to the media differs.  The two-way analysis of variance is an extension of the 
ANOVA that examines the influence of two different categorical independent variables on one 
continuous dependent variable. The use of two-way ANOVA is to understand if there is an 
relationship between the two independent variables which in this case, are CBD and THC, on the 
dependent variable which in this case is the apoptosis of the MCF-7 breast cancer cells shown in 
Figure 5 and 6. The P-values need to be equal to or less than 0.0500 to account for statistical 
significant differences between the variables.  
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 As illustrated in Table 1, the comparison of CBD and THC to media has a P value = 0.0598 which 
indicates that there is not any statistical significance, however, there is a significant difference 
among each concentration. As illustrated in Table 2, each concentration including the control were 
compared with all the concentrations to find a significant difference. All the concentrations show no 
significant difference except for the relationship between 10 µM THC and 100 µM CBD, which 
stipulate that at 100 µM CBD concentration, the concentration has an opposite effect on the MCF-7 
breast cancer cells compared to all the concentrations and the media.  
Table 1: MTT Assay Comparison of CBD 
and THC Treatment to the Media. 
Significant difference is P valve of 0.05 
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Table 2: Multiple Comparison of t-Test of Each Group to Every other Group. The difference is 
significant at P-valve ≤ 0.05. 
 
  
 
 Dunn's multiple comparisons test Significant? Adjusted P Value 
    
 Control vs. 0.1 µM THC No >0.9999 
 Control vs. 1 µM THC No >0.9999 
 Control vs. 10 µM THC No >0.9999 
 Control vs. 100 µM THC No >0.9999 
 Control vs. 0.1 µM CBD No >0.9999 
 Control vs. 1 CBD No >0.9999 
 Control vs. 10 CBD No >0.9999 
 Control vs. 100 CBD No >0.9999 
 0.1 µM THC vs. 1 µM THC No >0.9999 
 0.1 µM THC vs. 10 µM THC No 0.1868 
 0.1 µM THC vs. 100 µM THC No >0.9999 
 0.1 µM THC vs. 0.1 µM CBD No >0.9999 
 0.1 µM THC vs. 1 CBD No >0.9999 
 0.1 µM THC vs. 10 CBD No >0.9999 
 0.1 µM THC vs. 100 CBD No >0.9999 
 1 µM THC vs. 10 µM THC No >0.9999 
 1 µM THC vs. 100 µM THC No >0.9999 
 1 µM THC vs. 0.1 µM CBD No >0.9999 
 1 µM THC vs. 1 CBD No >0.9999 
 1 µM THC vs. 10 CBD No >0.9999 
 1 µM THC vs. 100 CBD No >0.9999 
 10 µM THC vs. 100 µM THC No 0.1868 
 10 µM THC vs. 0.1 µM CBD No >0.9999 
 10 µM THC vs. 1 CBD No >0.9999 
 10 µM THC vs. 10 CBD No >0.9999 
 10 µM THC vs. 100 CBD Yes 0.0108 
 100 µM THC vs. 0.1 µM CBD No >0.9999 
 100 µM THC vs. 1 CBD No >0.9999 
 100 µM THC vs. 10 CBD No >0.9999 
 100 µM THC vs. 100 CBD No >0.9999 
 0.1 µM CBD vs. 1 CBD No >0.9999 
 0.1 µM CBD vs. 10 CBD No >0.9999 
 0.1 µM CBD vs. 100 CBD No >0.9999 
 1 CBD vs. 10 CBD No >0.9999 
 1 CBD vs. 100 CBD No >0.9999 
 10 CBD vs. 100 CBD No >0.9999 
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ANOVA- Western Blot 
 As illustrated in Table 3, the comparison of CBD and THC to media is P value = 0.7364 
indicates that there is not any statistical significance. In addition, the P valve for all the 
concentrations also indicated that there is not any statistically significant difference between all 
these concentrations.  
 
Table 3: Western blot comparison of CBD and THC treatment to the media. 
Significant difference is when the P valve is 0.05 
  
ANOVA Column2 
P value 0.7364 
Exact or approximate P value? Approximate 
P value summary Ns 
Do the medians vary signif. (P < 0.05)? No 
Number of groups 10 
Kruskal-Wallis statistic 6.035 
  
Data summary  
Number of treatments (columns) 10 
Number of values (total) 24 
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Figure 6: Comparison of the THC and CBD to the media. B. Multiple comparison, t-test of each 
group to every other group.  
 
 
Discussion 
 
 In this study, the ascertainment of various concentrations of CBD and THC that influence 
MCF-7 breast cancer apoptosis was the focus. Studies have shown that certain cannabinoids 
cause the apoptosis of cancer cells, but only with a certain concentration, which has not been 
well documented. Therefore, this study was to determine the exact concentration of CBD and 
THC needed to kill MCF-7 breast cancer cells, rather than creating mass multiplication leading 
to more growth of the cancer. An MTT assay and Western blot were the methods used to conduct 
this experiment. The first study (Agyemang, D., & Hyslop, R., in press) stated that CBD was 
more effective at stimulating apoptosis compared to THC. However, the most effective 
concentration of CBD varied between the MTT assay and the Western blot assay. The first study 
(Agyemang, D., & Hyslop, R., in press) research results were preliminary; however, this research 
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is a replication with a larger sample sizes. This is a better representative of the population 
making the data more accurate and precise.  
 As illustrated in the MTT Assay, 100 µM is lower in proliferation in both CBD and THC 
which indicated inhibition of the MCF-7 breast cancer cells. The most salient finding is that 100 
µM CBD was the most effective concentration when looking at the MTT assay assessment. 
However, THC concentration results vary. At concentration of 100 µM, the THC inhibit the 
cancer growth, but at 10 µM concentration of THC increase proliferation, meaning the drugs 
stimulates a growth in the MCF-7 breast cancer cell. Visually, the MTT assay illustrated that 
CBD was more effective overall drug compared to THC, however the t-Test results indicate that 
there is not any statistically significant difference.  Blasco-Benito et al. (2018) suggested that the 
combination of cannabinoids with estrogen receptor- or HER2-targeted therapies (tamoxifen and 
lapatinih, respectively) or with cisplatin, produced additive anti-proliferative responses in cell 
cultures; THC and CBD did not show any significant different comparing to the control due to 
the lack of these combinations. Takeda et al. (2008) concluded that RT-PCR analysis 
demonstrated that there was no detectable expression of CB receptors in MCF-7 cells therefore 
cannabinoids had no effect on the cells. However, with the presence of CB receptors cause Δ9-
THC to inhibit the proliferation of MCF-7 cells.  
 As illustrated in the Western blot assessment, as the CBD concentrations increase, the 
apoptosis decreased in MCF-7 breast cancer cells. As illustrated in figure 4, 0.1 µM CBD 
concentration resulted in the most apoptosis comparing to all the CBD concentrations. Western 
blot results conflict with the MTT Assay; this may be due to fact that there was a larger sample 
size in the MTT assay then there was in the western blot. THC concentration had mixed effect on 
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the MCF-7 breast cancer cells. As illustrated in figure 4, 0.1 µM concentration was most 
effective for both CBD and THC.  
 However, the most effective concentrations of CBD and THC on the MCF-7 breast 
cancer cells as assessed by Western blot are different from MTT assay’s most effective 
concentration. Even though Western blot and MTT assay have different values of what 
concentration was effective, both methods show that there is indeed an apoptosis of MCF-7 
breast cancer cells due to the influence of CBD or THC.  However, this effective concentration 
was not statistically significant different. Petreocells et al. (1998) research indicated that 
anandamide works best on the MCF-7 breast cancer cell with concentrations of 5-10 µM which 
works by blocking human breast cancer cell proliferation through CBI-like receptor-mediated 
inhibition of endogenous prolactin action at the level of prolactin receptor.  
            Focusing on the Western blot, THC has the opposite effect at concentrations of 1 µM and 
100 µM indicating that there was no apoptosis among MCF-7 breast cancer cell or perhaps 
stimulated proliferation. Comparing the information to the MTT assay, 10 µM THC caused 
proliferation but for the Western blot it was 1 µM and 100 µM. The proliferation occurred in 
both methods proving that THC could perhaps stimulate proliferation instead of inhibitions of 
the MCF-7 breast cancer cells. Sarfaraz et al. (2008) stated that low doses of cannabinoids cause 
acceleration of proliferation of the cancer cells instead of inducing apoptosis.  Sarfarz et al. 
results were supported by THC concentration at 10 µM from MTT assay and 1 µM, 100 µM 
from Western blot assay.  
 Statistically, there is no significant difference between CBD and THC from the Western 
blot. Furthermore, there is no significant difference among all the concentrations from the 
Western blot, but visually there is trend. Even though the statistical data show no significant 
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difference between the media and the concentration, multiple reports such as Blasco-Benito et al. 
(2018), Sarfaraz et al. (2008), Velasco et al. (2016) and more have shown that cannabinoid do in 
fact cause anti-proliferation of cancer cells.  The lack of statistically significant difference in this 
research could be because the sample sizes were not quite large enough.  
 THC and CBD appeared to be effective on the MCF-7 cancer cells; 100 µM or 0.1 µM 
showed inhibition of MCF-7 cancer cells depending on either Western blot or the MTT assay 
was used. Moving forward, an alternative to the MTT assay could be used since MTT assay is 
not sensitive enough for the time points examined.  Using Western blot to narrow down between 
these two concentrations in which the drug causes inhibition of the proliferation of breast cancer 
and testing enough to get a statistically significant difference between the concentration of CBD 
and THC to media will be the next focus. Favorable findings may provide an accessible and 
affordable cannabinoid-based treatment for patients. 
Conclusions 
 CBD and THC appeared to be effective at stimulating apoptosis of the MCF-7 breast 
cancer cells, however, there was no statistically significant difference. Western blot illustrated 
that at 0.1 µM, CBD and THC are the most effective at stimulating inhibition of the MCF-7 
human breast cancer cells, while MTT assay illustrated that at 100 µM, CBD and THC are most 
effective at stimulating apoptosis of the MCF-7 breast cancer cells. Since Western blot is the 
more reliable method, the concentration provided from the western blot should be the focus, 
however, the sample size for the western blot was small. Therefore, a larger sample sizes for the 
western blot will be the next focus.  
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